Hope for Lung Cancer Patients: Cypath Lung Test's Impact

bioAffinity Technologies, Inc. (NASDAQ: BIAF) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung , is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath ® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services , a subsidiary of bioAffinity Technologies. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   bioAffinity (BIAF) is a client of RedChip Companies, Inc. BIAF agreed to pay RedChip Companies, Inc. an $8,500 monthly cash fee, beginning in October 2023 , and 50,000 shares of Rule 144 stock (subject to board approval) for 12 months of investor awareness services. BIAF also agreed to pay RedChip a one-hundred-thousand dollar fee for national TV ad campaigns, aired in February and April 2024, and a thirty-thousand dollar fee for a national TV ad campaign aired in September 2024.   For full disclosure, visit RedChip.com/disclosures.